Asuragen, Inc. Launches miRInform® Pancreas Test for use on Fine Needle Aspirate Specimens of Pancreatic Masses

AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc. announced today the immediate availability of the miRInform® Pancreas Test in its CAP-accredited CLIA Laboratory. miRInform® Pancreas was developed to aid physicians in the diagnosis and management of pancreatic ductal adenocarcinoma (PDAC) when cytology is inconclusive. The test evaluates expression levels of seven miRNAs in Fine Needle Aspirate (FNA) specimens of pancreatic masses.

Back to news